---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-24-000099"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:51:55.176151+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcus reports Phase 2 EDGE-Gastric interim data: median PFS 12.9 months, ORR 58.5% in upper GI cancers

## Summary
- Median PFS of 12.9 months (95% CI 9.8–13.8) across 41 patients in the domvanalimab+zimberelimab+chemo arm.
- Confirmed ORR 58.5%, with 3 complete responses and median DOR of 12.4 months (95% CI 9.9–NE).
- PD-L1-high subgroup (TAP ≥5%) showed median PFS 13.8 months and ORR 68.8% (n=16).
- No unexpected safety signals; infusion-related reactions in 19.5% of subjects, mostly chemotherapy-related.
- Data cutoff March 12, 2024; results posted to company website on June 2, 2024.

## SEC filing metadata
- accession: 0001724521-24-000099
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000099/0001724521-24-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452124000099/rcus-20240602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-24-000099
- JSON: https://secwatch.observer/filing/0001724521-24-000099.json
- Plain text: https://secwatch.observer/filing/0001724521-24-000099.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.